BlueCross and BlueShield of Montana Medical Policy/Codes
Stem-Cell Transplant for Chronic Myelogenous Leukemia
Chapter: Transplant
Current Effective Date: October 25, 2013
Original Effective Date: July 09, 2008
Publish Date: October 25, 2013
Revised Dates: November 15, 2011; September 25, 2013

CML is a hematopoietic stem-cell disorder that is characterized by the presence of a chromosomal abnormality called the Philadelphia chromosome, which results from reciprocal translocation between the long arms of chromosomes nine and 22.  This cytogenetic change results in constitutive activation of BCR-ABL (breakpoint cluster region-Abelson murine leukemia), a tyrosine kinase (TK) that stimulates unregulated cell proliferation, inhibition of apoptosis, genetic instability, and perturbation of the interactions between CML cells and the bone marrow stroma only in malignant cells.

The natural history of the disease consists of an initial (indolent) chronic phase, lasting a median of three years that typically transforms into an accelerated phase, followed by a "blast crisis," which is usually the terminal event.  Conventional-dose regimens used for chronic-phase disease can induce multiple remissions and delay the onset of blast crisis to a median of 4–6 years. However, successive remissions are invariably shorter and more difficult to achieve than their predecessors.

Imatinib mesylate (Gleevec®), a selective inhibitor of the abnormal BCR-ABL TK protein, is considered the treatment of choice for newly diagnosed CML.  While imatinib can be highly effective in suppressing CML in most patients, it is not curative and is ineffective in 20% to 30%, initially or due to development of BCR-ABL mutations that cause resistance to the drug. Two other TK inhibitors (TKIs, dasatinib, nilotinib) have received marketing approval from the U.S. Food and Drug Administration (FDA) to treat CML following failure or patient intolerance of imatinib.  In any case, allogeneic SCT remains the only treatment capable of inducing durable remissions or cure in CML patients.


Each benefit plan or contract defines which services are covered, which are excluded, and which are subject to dollar caps or other limits.  Members and their providers have the responsibility for consulting the member's benefit plan or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply.  If there is a discrepancy between a Medical Policy and a member's benefit plan or contract, the benefit plan or contract will govern.


Coverage for evaluation of and subsequent single treatment by stem-cell transplant (SCT) (using bone marrow, peripheral blood, or umbilical cord blood as a stem-cell source), derived from a specific donor category, and following a chemotherapy regimen for treatment of chronic myelogenous leukemia (CML) is identified in the grid below.


May be considered medically necessary to treat chronic myelogenous leukemia.


Is considered experimental, investigational and unproven.

Tandem or Triple Stem-Cell Transplant

Is considered experimental, investigational and unproven. 

Donor Leukocyte Infusion

Is considered experimental, investigational and unproven.


High-dose chemotherapy (HDC) followed by hematopoietic stem-cell (HSC) (i.e., blood or marrow) transplant is an effective treatment modality for many patients with certain malignancies and non-malignancies.  The rationale of this treatment approach is to provide a very dose-intensive treatment in order to eradicate malignant cells followed by rescue with peripheral blood or bone marrow stem-cells. 

This policy is based on a 1986 Blue Cross Blue Shield Association (BCBSA) Technology Evaluation Center (TEC) Assessment that addressed the use of allogeneic stem-cell transplant (SCT) as a treatment of CML and a 1994 TEC Assessment that addressed the use of autologous SCT.  The 1986 Assessment concluded that allogeneic SCT met the TEC criteria.  Since that time, allogeneic transplant has emerged as the standard treatment of CML when a suitable stem-cell donor is available.  It is estimated that patients in chronic phase receiving an HLA (human leukocyte antigen )-matched sibling donor transplant have a 45–75% probability of long-term disease-free survival, while those transplanted with more advanced disease have a 15%–40% long-term survival.  Young, good-risk patients transplanted early in the chronic phase from HLA-matched but unrelated donors reportedly have a 40–60% probability of long-term survival, although it is lower than that of similar patients transplanted from matched sibling donors.  With the availability of imatinib mesylate, allogeneic transplants may be used less often to manage patients with CML, or they may only be used when a complete molecular response to the drug fails or is not achieved.  These uncertainties will be resolved only after additional clinical studies are performed and longer follow-up is available.

Obvious limitations of allogeneic stem cells are the lack of a suitable donor for many patients and the increased morbidity of allogeneic transplant in older patients.  An obvious limitation of autologous stem cells is the near certainty that leukemic cells will be infused back into the patient.  The 1994 TEC Assessment concluded that autologous SCT did not meet the TEC criteria.  However, it is recognized that many CML patients still have normal marrow stem cells, and research has focused on ways to isolate and expand this normal clone of cells.  Techniques used have included ex vivo purging, long-term culture, and immunophenotype selection.  Even without such techniques, there have been isolated case reports of partial cytogenetic remissions after autologous SCT, and one study has suggested that patients undergoing such therapy may have improved survival compared with historical controls.

A 1994 article summarized the results of 200 consecutive autologous transplants using purged or non-purged marrow from eight different transplant centers.  Of the 200 patients studied, 125 were alive at a median follow-up of 42 months.  Of the 142 transplanted in chronic phase, the median survival had not been reached at the time of publication, while the median survival was 35.9 months for those transplanted during an accelerated phase.  Other data consist of small, single institution case series using a variety of techniques to enrich the population of normal stem cells among the harvested cells. 

A search for literature from 2002 on autologous transplantation found no comparative trials, but identified several new reports from small, uncontrolled studies with a total of 182 patients (range: 15–41 patients) given autotransplants for CML.  Patient populations varied across these studies.  Some focused on newly diagnosed patients or those in the first year since diagnosis.  Others focused on patients who did not respond to or relapsed after initial treatment using interferon alfa.  Finally, some focused on patients transplanted in the late chronic phase or after transformation to accelerated phase or blast crisis.  Although some patients achieved complete or partial molecular remissions and long-term disease-free survival, these studies do not permit conclusions free from the influence of patient selection bias.  Note also that all autotransplanted patients included in these reports were treated before imatinib mesylate (Gleevec) became available.  Since this drug has been shown to induce major hematologic and, less often, cytogenetic remissions, even among patients in accelerated phase and blast crisis, future studies of autotransplants for CML may focus on patients who fail or become resistant to imatinib mesylate.  Alternatively, it may be incorporated into combination regimens used for high-dose therapy.

2007 National Comprehensive Cancer Network (NCCN) Guidelines

The 2007 NCCN guidelines on CML (V.2.2007) recommend allogeneic bone marrow transplant for treatment of primary CML and CML with disease progression.  Autologous bone marrow transplant for CML is not addressed in these NCCN guidelines.  Since response rates with imatinib (Gleevec) have been favorable as an initial treatment option, the NCCN mentions it is not clear whether allogeneic SCT should still be included as a front line treatment.  However, since allogeneic SCT has been proven to be an effective therapy, the NCCN determined that it should continue to be included as a front line treatment option.  The National Cancer Institute concurs that allogeneic SCT remains the only known curative option for CML. 

Additional Review of Literature Through 2008

Allogeneic SCT became the standard therapy for CML in the 1980s when the graft-versus-leukemia (GVL) effect was shown to be the critical factor for long-term disease control.  Since then, this procedure has continued to evolve, with important advancements in the use of nonmyeloablative or reduced-intensity conditioning (RIC) preparative regimens. RIC regimens were initially conceptualized as a means to extend the use of allogeneic SCT to the estimated 70% of CML patients who were ineligible for myeloablative conditioning regimens because of advanced age or comorbidities.  The use of RIC and allogeneic SCT is of particular interest for treatment of CML given the relatively pronounced susceptibility of this malignancy to the GVL effect of allogeneic hematopoietic progenitor cells following their engraftment in the host. Overall, among nine studies compiled in a recent review, outcomes achieved with RIC allogeneic transplants have been similar to those with conventional allotransplants, with overall survival (OS) rates ranging from 35% at 2.5 years to 85% at five years among patients in chronic phase I at transplant.  Among the studies included in this review, treatment-related mortality or non relapse mortality ranged from 0% at one year to 29% at one year.  In the largest experience, a retrospective European Group for Blood and Marrow Transplantation (EMBT) study of 186 patients, OS was 54% at three years using a variety of RIC regimens in patients in chronic phase I (n=118), chronic phase II (n=26), acute phase (n=30), and blast crisis (n=12).  Among patients transplanted in the first chronic phase (CP1), OS was 69% at three years.  

CML was once the most common malignancy for which allogeneic SCT was performed, but by 2005 it was in eighth place among hematologic transplantation indications.  A retrospective analysis of data from the Center for International Blood and Marrow Transplant Research Center (CIBMTR) showed that transplantation for CML was in decline prior to FDA approval of imatinib in 2001.  It is clear RIC allogeneic SCT will continue to evolve, perhaps supplanting myeloablative conditioning regimens for select patients.  However, the scientific evidence available to date does not provide direct comparison of health outcomes with sufficiently long follow-up in similar patient groups to draw conclusions about the net health benefit of this therapeutic approach.  It also seems unlikely that properly designed and powered trials will be conducted to compare standard allogeneic SCT with RIC allogeneic SCT in CML patients clearly eligible for transplant, largely because the two methods are applied to different patient populations and given the effectiveness and primary role of FDA-approved TKIs.

The 2008 NCCN guidelines on CML recommend allogeneic bone marrow transplant as an alternative treatment option only for the following high-risk settings:

  • patients who do not achieve hematologic remission after three months of imatinib therapy;
  • patients with no cytogenetic response or those in cytogenetic relapse at six, 12, or 18 months, after achieving initial hematologic remission after three months of imatinib therapy;
  • patients progressing on imatinib to accelerated phase or blast crisis.

Autologous bone marrow transplant for CML is not addressed in the NCCN guidelines.

The 2008 National Cancer Institute (NCI) clinical trial database (PDQ®) identified six active randomized trials in the United States that involve stem-cell support for patients with CML.

Trials include allografting, using various conditioning regimens, as well as different stem-cell sources and mobilization protocols.

Tandem or Triple Stem-Cell Transplant and Donor Leukocyte Infusion (DLI) for CML are considered experimental, investigational, and unproven due to lack of adequate evidence of safety and effectiveness documented in published, peer-reviewed medical literature.


Disclaimer for coding information on Medical Policies           

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy.  They may not be all-inclusive.           

The presence or absence of procedure, service, supply, device or diagnosis codes in a Medical Policy document has no relevance for determination of benefit coverage for members or reimbursement for providers.  Only the written coverage position in a medical policy should be used for such determinations.           

Benefit coverage determinations based on written Medical Policy coverage positions must include review of the member’s benefit contract or Summary Plan Description (SPD) for defined coverage vs. non-coverage, benefit exclusions, and benefit limitations such as dollar or duration caps. 

ICD-9 Codes

41.00, 41.01, 41.02, 41.03, 41.04, 41.05, 41.06, 41.07, 41.08, 41.09, 41.91, 99.25, 99.74, 99.79, 205.10, 205.11

Procedural Codes: 36511, 38204, 38205, 38206, 38207, 38208, 38209, 38210, 38211, 38212, 38213, 38214, 38215, 38220, 38221, 38230, 38232, 38240, 38241, 38242, 38243, 81265, 81266, 81267, 81268, 81370, 81371, 81372, 81373, 81374, 81375, 81376, 81377, 81378, 81379, 81380, 81381, 81382, 81383, 86805, 86806, 86807, 86808, 86812, 86813, 86816, 86817, 86821, 86822, 86825, 86826, 86849, 86950, 86985, 88240, 88241
  1. Bone Marrow Transplantation - Allogeneic. Chicago, Illinois: Blue Cross Blue Shield Association – Technology Evaluation Center (1986 April):43-7.
  2. High-Dose Chemotherapy with Autologous Stem-Cell Support for Chronic Myelogenous Leukemia. Chicago, Illinois: Blue Cross Blue Shield Association – Technology Evaluation Center Assessment Program (1994 March) 9(3):1-14.
  3. McGlave, P.B., De Fabritiis, P., et al. Autologous transplants for chronic myelogenous leukemia: results from eight transplant groups. Lancet (1994) 343(8911):1486-8.
  4. Bhatia, R., Verfaillie, C.M., et al. Autologous transplantation therapy for chronic myelogenous leukemia. Blood (1997) 89(8):2623-34.
  5. Szatrowski, T.P. Progenitor cell transplantation for chronic myelogenous leukemia. Seminars in Oncology (1999) 26(1):62-6.
  6. Pigneux, A., Faberes, C., et al. Autologous stem cell transplantation in chronic myeloid leukemia: a single center experience. Bone Marrow Transplant (1999) 24(3):265-70.
  7. Boiron, J.M., Cahn, J.Y., et al. Chronic myeloid leukemia in first chronic phase not responding to alpha-interferon: outcome and prognostic factors after autologous transplantation. EBMT Working Party on Chronic Leukemias. Bone Marrow Transplant (1999) 24(3):259-64.
  8. McGlave, P.B., Shu, X.O., et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood (2000) 95(7):2219-25.
  9. Podesta, M., Piaggio, G., et al. Autografting with Ph-negative progenitors in patients at diagnosis of chronic myeloid leukemia induces a prolonged prevalence of Ph-negative hemopoiesis. Experimental Hematology (2000) 28(2):210-5.
  10. McBride, N.C., Cavenagh, J.D., et al. Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon. Bone Marrow Transplant (2000) 26(11):1165-72.
  11. Michallet, M., Thiebaut, A., et al. Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-alpha. Leukemia (2000) 14(12):2064-9.
  12. Druker, B.J., Sawyers, C.L., et al. Chronic myelogenous leukemia. In: Hematology (2001) (American Society of Hematology Education Program Book); GP Schechter, VC Broudy, ME Williams (eds.). Washington, DC: American Society of Hematology, (2001) pp. 87-112.
  13. Meloni, G., Capria, S., et al. Ten-year follow-up of a single center prospective trial of unmanipulated peripheral blood stem cell autograft and interferon-alpha in early phase chronic myeloyd leukemia. Haematologica (2001) 86(6):596-601.
  14. Weisdorf, D.J., Anasetti, C., et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood (2002) 99(6):1971-7.
  15. O'Dwyer, M.E., Mauro, M.J., et al. Recent advancements in the treatment of chronic myelogenous leukemia. Annual Review of Medicine (2002) 53:369-81.
  16. Garcia-Manero, G., Talpaz, M., et al. Current therapy of chronic myelogenous leukemia. Internal Medicine (2002) 41(4):254-64.
  17. Donor Leukocyte Infusion for Hematologic Malignancies that Relapse after Allogeneic Stem Cell Transplant. BCBSA Medical Policy Reference Manual (2005 September) Medicine: 2.03.03.
  18. Crawley, C., Szydlo, R., et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood (2005) 106(9):2969-76.
  19. Mauro, M.J., Deininger, M.W. Chronic myeloid leukemia in 2006: a perspective. Haematologica (2006) 91(2):152-8. Available online at .
  20. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. V.2.2007. Available online .
  21. Chakrabarti, S., Buyck, H.C. Reduced-intensity transplantation in the treatment of haematological malignancies: current status and future prospects. Current Stem Cell Research Therapy (2007) 2(2):163-88.
  22. Giralt, S.A., Arora, M., et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. British Journal of Haematology (2007) 137(5):461-7.
  23. Maziarz, RT. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors? Current Opinions in Hematology (2008) 15(2):127-33.
  24. National Cancer Institute. Chronic Myelogenous Leukemia (PDQ®): Treatment (Health Professional Version v.2. 2009).  ©2008. Available online at .
  25. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. V.3.2008. Available online at
  26. Hematopoietic Stem-Cell Transplantation for Chronic Myelogenous Leukemia. Chicago, Illinois: Blue Cross Blue Shield Association Medical Policy Reference Manual (2008 June) Therapy: 8.01.30.
 July 2011 Policy name changed from general Leukemia SCT to specific Chronic Myelogenous Leukemia.
October 2013 Policy formatting and language revised.  Policy statement unchanged.  Title changed from "Hematopoietic Stem-Cell Transplantation for Chronic Myelogenous Leukemia" to "Stem-Cell Transplant for Chronic Myelogenous Leukemia".
®Registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. ®LIVE SMART. LIVE HEALTHY. is a registered mark of BCBSMT, an independent licensee of the Blue Cross and Blue Shield Association, serving the residents and businesses of Montana.
CPT codes, descriptions and material only are copyrighted by the American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in CPT. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS Restrictions Apply to Government Use. CPT only © American Medical Association.
Stem-Cell Transplant for Chronic Myelogenous Leukemia